The role of Testosterone Therapy (TTh) in the management of male sexual dysfunction remains unclear. Objective of the authors was to systematically review the relevant literature assessing the benefits and harms of TTh in men with sexual dysfunction. EMBASE, MEDLINE, Cochrane Systematic Reviews—Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane HTA, DARE, HEED), Google Scholar, WHO international Clinical Trials Registry Platform Search Portal, CINAHL databases and clinicaltrial.gov were searched systematically in March 2015 and an updated search was performed in March 2016. Randomized and non-randomized comparative studies assessing the benefits and harms of TTh in hypogonadal, borderline eugonadal and eugonadal men suffering from sexual dysfunction were included. Risk of bias and confounding assessments were performed. A narrative synthesis was undertaken. Of the 6410 abstracts identified, 36 studies were judged to be eligible for inclusion, including 25 randomized clinical trials (RCTs) and 11 non-randomized comparative studies (NRCSs), recruiting a total of 4944 patients. RCTs were judged to have low or unclear risk of bias, while NRCSs had high risk of bias and thus, overall quality of evidence was judged to be at least unclear. Based on the evidence mainly provided by the RCTs included in this systematic review, TTh could be considered for men with low or low-normal testosterone levels and problems with their sexual desire, erectile function and satisfaction derived from intercourse and overall sexual life. The exact testosterone formulation, dosage and duration of treatment remain to be clarified, while the safety profile of TTh also remains unclear. TTh could be used with caution in hypogonadal and most probably borderline eugonadal men to manage disorders of sexual desire, erectile function and sexual satisfaction. The overall low-to-moderate evidence quality highlights the need for robust and adequately designed clinical trials.
Subscribe to Journal
Get full journal access for 1 year
only $32.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, et al. Definitions of sexual dysfunctions in women and men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13:135–43. https://doi.org/10.1016/j.jsxm.2015.12.019
Antonio L, Wu FCW, O’Neill TW, Pye SR, Ahern TB, Laurent MR, et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab. 2016;101:2647–57. https://doi.org/10.1210/jc.2015-4106
O’Connor DB, Lee DM, Corona G, Forti G, Tajar A, O’Neill TW, et al. The relationships between sex hormones and sexual function in middle-aged and older European men. J Clin Endocrinol Metab. 2011;96:E1577–1587. https://doi.org/10.1210/jc.2010-2216
Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10:245–84. https://doi.org/10.1111/j.1743-6109.2012.02783.x
Wu FCW, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–35. https://doi.org/10.1056/NEJMoa0911101
Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99–112. https://doi.org/10.1016/j.eururo.2013.08.048
Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93:3870–7. https://doi.org/10.1210/jc.2008-0021
Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102:1067–75. https://doi.org/10.1210/jc.2016-3580
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995–2010. https://doi.org/10.1210/jc.2005-2847
Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15. https://doi.org/10.3109/13685538.2015.1004049
Khera M, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Diagnosis and treatment of testosterone deficiency: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2016;13:1787–804. https://doi.org/10.1016/j.jsxm.2016.10.009
NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA. 1993;270:83–90.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:1–173.
Reeves BC, Deeks JJ, Higgins J, Wells GA Cochrane Non-Randomized Studies Methods Group. Including non-randomised studies. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration Web site. http://www.cochrane-handbook.org. Accessed 24 August 2017.
Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A Product from the ESRC Methods Programme. (Vol. 1). Bailrigg: Lancaster University; (2006). p. 1–92.
Schiavi RC, White D, Mandeli J, Levine AC. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav. 1997;26:231–41.
Wagner G, Rabkin J, Rabkin R. Effects of testosterone replacement therapy on sexual interest, function, and behavior in HIV + men. J Sex Res. 1997;34:27–33. https://doi.org/10.1080/00224499709551861
Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141–7. discussion155-156
Gomaa A, Eissa M, El-Gebaley A. The effect of topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int J Impot Res. 2001;13:93–9. https://doi.org/10.1038/sj.ijir.3900643
Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003;58:632–8.
Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1–7.
Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004;63:641–6. https://doi.org/10.1016/j.urology.2003.11.009
Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–63. https://doi.org/10.1097/01.ju.0000132389.97804.d7
Schrader S, Mills A, Scheperle M, Block JE. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males. Clin Cornerstone. 2005;7(Suppl 4):S26–31.
Shamloul R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med. 2005;2:559–64. https://doi.org/10.1111/j.1743-6109.2005.00071.x
Steidle C, Witt MA, Matrisciano J, Block JE. Sexual functioning and satisfaction in nonresponders to testosterone gel: potential effectiveness of retreatment in hypogonadal males. Clin Cornerstone. 2005;7(Suppl 4):S20–25.
Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Int J Androl. 2006;29:381–91. https://doi.org/10.1111/j.1365-2605.2005.00612.x
Rochira V, Balestrieri A, Madeo B, Granata ARM, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl. 2006;27:165–75. https://doi.org/10.2164/jandrol.05077
Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006;38:61–8. https://doi.org/10.1111/j.1439-0272.2006.00712.x
Richardson D, Goldmeier D, Frize G, Lamba H, De Souza C, Kocsis A, et al. Letrozole versus testosterone. a single-center pilot study of HIV-infected men who have sex with men on highly active anti-retroviral therapy (HAART) with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med. 2007;4:502–8. https://doi.org/10.1111/j.1743-6109.2007.00451.x
Morales A, Black A, Emerson L, Barkin J, Kuzmarov I, Day A. Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male. 2009;12:104–12. https://doi.org/10.3109/13685530903294388
Herzog AG, Farina EL, Drislane FW, Schomer DL, Smithson SD, Fowler KM, et al. A comparison of anastrozole and testosterone versus placebo and testosterone for treatment of sexual dysfunction in men with epilepsy and hypogonadism. Epilepsy Behav. 2010;17:264–71. https://doi.org/10.1016/j.yebeh.2009.12.003
Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284–93. https://doi.org/10.1111/j.1743-6109.2010.01956.x
Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157:681–91. https://doi.org/10.7326/0003-4819-157-10-201211200-00004
Mitkov MD, Aleksandrova IY, Orbetzova MM. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv). 2013;55:55–63.
Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, et al. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med. 2015;12:966–74. https://doi.org/10.1111/jsm.12842
Brock G, Heiselman D, Maggi M, Kim SW, Rodríguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699–705. https://doi.org/10.1016/j.juro.2015.10.083
Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100:2956–62. https://doi.org/10.1210/jc.2014-4434
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611–24. https://doi.org/10.1056/NEJMoa1506119
Aydin S, Odabaş O, Ercan M, Kara H, Ağargün MY. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol. 1996;77:256–60.
Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 1998;31:313–9.
Monga M, Kostelec M, Kamarei M. Patient satisfaction with testosterone supplementation for the treatment of erectile dysfunction. Arch Androl. 2002;48:433–42. https://doi.org/10.1080/01485010290099174
Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male. 2003;6:86–93.
Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol. 2005;173:530–2. https://doi.org/10.1097/01.ju.0000149870.36577.05
Hwang TI-S, Chen H-E, Tsai T-F, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18:400–4. https://doi.org/10.1038/sj.ijir.3901446
Tas A, Ersoy A, Ersoy C, Gullulu M, Yurtkuran M. Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. Int J Impot Res. 2006;18:61–8. https://doi.org/10.1038/sj.ijir.3901372
Hassan A, El-Hadidy M, El-Deeck BS, Mostafa T. Couple satisfaction to different therapeutic modalities for organic erectile dysfunction. J Sex Med. 2008;5:2381–91. https://doi.org/10.1111/j.1743-6109.2007.00697.x
Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008;29:102–5. https://doi.org/10.2164/jandrol.107.002774
Yassin D-J, Yassin AA, Hammerer PG. Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone. J Sex Med. 2014;11:543–52. https://doi.org/10.1111/jsm.12378
Labairu-Huerta L, Padilla-Fernández B, Arrondo-Arrondo JL, Valverde-Martínez LS, Martín-Rodríguez A, Silva-Abuín JM, et al. PDE-5 inhibitors in monotherapy versus combination therapy in a sample of 1200 patients with erectile dysfunction. Arch Ital Urol Androl. 2015;87:204–9. https://doi.org/10.4081/aiua.2015.3.204
Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–9. https://doi.org/10.3109/13685538.2015.1126573
Corona G, Rastrelli G, Morgentaler A, Sforza A, Mannucci E, Maggi M.Meta-analysis of results of testosterone therapy on sexual function based on international index of erectile function scores.Eur Urol. 2017;72:1000–1011.
Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577–92. https://doi.org/10.1111/jsm.12536
Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63:381–94. https://doi.org/10.1111/j.1365-2265.2005.02350.x
Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol. 2000;164:371–5.
Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:20–8. https://doi.org/10.4065/82.1.20
Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab. 2016;101:3096–104. https://doi.org/10.1210/jc.2016-1645
Wu F, Zitzmann M, Heiselman D, Donatucci C, Knorr J, Patel AB, et al. Demographic and clinical correlates of patient-reported improvement in sex drive, erectile function, and energy with testosterone solution 2. J Sex Med. 2016;13:1212–9. https://doi.org/10.1016/j.jsxm.2016.05.010
Huo S, Scialli AR, McGarvey S, Hill E, Tügertimur B, Hogenmiller A, et al. Treatment of men for “Low Testosterone”: a systematic review. PLoS ONE. 2016;11:e0162480 https://doi.org/10.1371/journal.pone.0162480
Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151:650–61. https://doi.org/10.7326/0003-4819-151-9-200911030-00150
Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012;15:22–7. https://doi.org/10.3109/13685538.2011.650246
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
Derogatis LR, Melisaratos N. The DSFI: a multidimensional measure of sexual functioning. J Sex Marital Ther. 1979;5:244–81. https://doi.org/10.1080/00926237908403732
O’Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, et al. A brief male sexual function inventory for urology. Urology. 1995;46:697–706. https://doi.org/10.1016/S0090-4295(99)80304-5
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–42. https://doi.org/10.1053/meta.2000.8625
Heinemann LAJ, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new ‘aging males’ symptoms’ rating scale. Aging Male. 1999;2:105–14. https://doi.org/10.3109/13685539909003173
Cabral RD, Busin L, Rosito TE, Koff WJ. Performance of Massachusetts Male Aging Study (MMAS) and androgen deficiency in the aging male (ADAM) questionnaires in the prediction of free testosterone in patients aged 40 years or older treated in outpatient regimen. Aging Male. 2014;17:147–54. https://doi.org/10.3109/13685538.2014.908460
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dimitropoulos, K., Verze, P., Van den Broeck, T. et al. What are the benefits and harms of testosterone therapy for male sexual dysfunction?—a systematic review. Int J Impot Res 31, 380–391 (2019). https://doi.org/10.1038/s41443-019-0131-1
Development of a visual tool to assess six dimensions of health and its validation in patients with endocrine disorders
Wiener klinische Wochenschrift (2021)
Archives of Endocrinology and Metabolism (2019)